INTRODUCTION
Programmed death ligand 1 and 2 (PD-L1 and PD-L2) engage the programmed death receptor 1 (PD-1) on T cells and induce PD-1 signaling, which then causes multiple effects in T cells including exhaustion (1), alterations in glycolytic and mitochondrial metabolism (2) , and reduced cell cycle activity (3) . Tumor cells expressing PD-1 ligands on their surface use the PD-1 pathway to evade an effective antitumor immune response, and blockade of PD-1 is particularly effective in tumors with a high mutational burden (4) . Genetic alterations including oncogenic activation of Myc (5) and loss of the tumor suppressor phosphatase and tensin homolog (6) cause increased PD-L1 expression (7) . JAK2 (Janus kinase 2) and PD-L1 are both localized on chromosome 9p. 24 . In Hodgkin's lymphoma patients, transcription of the PD-L1 gene is increased upon amplification of chromosome 9p24.1 (8) (9) (10) . It was initially unclear whether, comparable to the amplification of chromosome 9p24.1 causing higher JAK2 and PD-L1 copy numbers, oncogenic JAK2 activity can also induce PD-L1 expression and if so, whether this event is functionally causative for immune escape. A group of diseases characterized by oncogenic JAK2 activity are myeloproliferative neoplasms (MPNs). Most MPN patients carry an activating point mutation in the JAK2 kinase (JAK2 V617F ). Because MPNs are potentially immunogenic neoplasms, as demonstrated by their susceptibility to interferon 2b (IFN-2b) (11) and detection of JAK2-specific T cells (12) , we decided to clarify whether there is a role for PD-L1 in this type of disease. We found that JAK2 V617F activity causes signal transducer and activator of transcription 3 (STAT3) and STAT5 phosphorylation, which in turn enhances PD-L1 promoter activity and increases PD-L1 protein expression. Both in murine MPN models and in primary patient samples, megakaryocytes, monocytes, and platelets expressed PD-L1 more abundantly compared to either wild-type (WT) littermates or healthy individuals. Consistent with the high PD-L1 expression observed, JAK2 
RESULTS

JAK2 activation enhances PD-L1 expression via STAT3 phosphorylation
To test whether oncogenic JAK2 activity increases PD-L1 expression, we used a Jak2 V617F knock-in mouse model that develops polycythemia vera (13) . In this model, we observed that PD-L1 surface expression was increased on megakaryocytes and monocytes derived from Jak2 V617F mice compared to Jak2-WT littermate control mice (Fig. 1 , A and B, and fig. S1 ). PD-L1 expression also increased in primary murine bone marrow (BM) cells upon transfection with a JAK2 V617F vector (Fig. 1C ), indicating that JAK2 was responsible for the increase of PD-L1 surface expression in different cell types. The previously described four point one/ezrin/radixin/moesin (FERM) domain mutation (14) , which causes oncogenic JAK2 activation (JAK2 FERM ), also increased PD-L1 expression (Fig. 1D) .
To understand the connection between oncogenic JAK2 and PD-L1, we transfected murine myeloid 32D cells with either a JAK2-WT vector or a JAK2 V617F vector (14) . 32D cells are erythropoietin-dependent (15) and have high endogenous PD-L1 expression. In the absence of erythropoietin, PD-L1 expression is lower, and under these conditions, PD-L1 expression increased in cells carrying the JAK2 V617F mutation (Fig. 1 , E and F). The same effects of mutant JAK2 on PD-L1 expression were seen in lymphoid Ba/F3 cells ( fig. S2, A and B) .
Treatment with the JAK1/2 inhibitor ruxolitinib reduced PD-L1 expression in JAK2
V617F
-mutant 32D cells (Fig. 1, G and H) and Ba/F3 cells ( fig. S2C ). In contrast, when Ba/F3 cells contained a JAK2 V617F/L983F mutation conferring ruxolitinib resistance, the PD-L1 expression declined less ( fig. S2D ). JAK2-specific inhibition with SD-1029 reduced PD-L1 expression in JAK2 V617F -mutant 32D (Fig. 1I) and Ba/F3 cells ( fig. S2 , E and F) in a dose-dependent manner, without major cytotoxic effects at the concentrations applied ( fig. S2G ).
To test our hypothesis that JAK2 activation enhances PD-L1 promoter activity via STAT phosphorylation, we analyzed phosphorylated STAT1 (pSTAT1), pSTAT3, and pSTAT5 in the presence of oncogenic JAK2 V617F . Active tyrosine pSTAT3 and pSTAT5 were increased in JAK2
-mutant 32D cells compared to JAK2-WT 32D cells and, to a lesser extent, pSTAT1 also increased (Fig. 1, J Then, to understand which pathway is involved in promoting PD-L1 expression, we made use of vectors expressing STAT proteins with gain-of-function (GOF) or loss-of-function (LOF) mutations. The STAT3-activating mutation Y640F (16) increased the expression of PD-L1 on 32D cells compared to STAT3-WT vector (Fig. 1L) . A similar pattern was observed in Ba/F3 cells with an activating STAT3 mutation ( fig. S2L) . Conversely, the STAT3 LOF mutations R382W and V637M reduced the expression of PD-L1 in JAK2 V617F -mutant 32D cells (Fig. 1M) and Ba/F3 cells ( fig. S2M) . Consistent with the idea that JAK2/STAT3 and PD-L1 are functionally connected, inhibition of STAT3 phosphorylation reduced PD-L1 expression ( fig. S2N ). In addition, a STAT5 GOF mutation (17) caused increased PD-L1 expression, although to a lesser extent than the STAT3 GOF mutation (Fig. 1L ). Consistent with a role for STAT5, the inhibition of STAT5 phosphorylation slightly reduced PD-L1 expression in 32D cells ( fig.  S2O ) and Ba/F3 cells ( fig. S2P) . A STAT1 GOF mutation had no significant effect on PD-L1 expression (Fig. 1L ). Our data are consistent with findings by others showing that STAT3 and STAT5 can bind the PD-L1 promoter (18) .
To evaluate the concept that JAK2 inhibition blocks immune responses in MPN, we analyzed the amount of serum IFN- in mice bearing a JAK2 V617F MPN, which were treated with ruxolitinib or vehicle. We observed that ruxolitinib reduced IFN- ( fig. S3 ). In light of these findings, it is likely that, although therapeutic JAK2 inhibition will render MPN more immunogenic on the basis of reduced PD-L1 expression, this intervention will at the same time counteract the T cell immune response against MPN.
In contrast to JAK2
, other oncogenic mutations, including FLT3-ITD, FLT3-TKD, cKIT (D816V), epidermal growth factor receptor (Del19, L861Q, and L858R), or platelet-derived growth factor receptor (FIP1L1-PDGFRA), did not increase PD-L1 surface expression ( fig. S4, A and B) . Because some of these mutations are found in acute myeloid leukemia (AML) (19, 20) , we analyzed the BM of AML patients and found that AML cells were mostly PD-L1-negative ( fig. S4, C and D) . Consistently, pSTAT3 abundance was also low in primary human AML cells ( fig. S4 , E and F).
JAK2 activation enhances PD-L1 expression in human cells
To evaluate whether the data obtained in murine cells were also applicable to human cells, we studied JAK2-WT or JAK2 V617F human cell lines. Transfection of K562 cells that express the ecotropic retrovirus receptor (21) with JAK2 V617F increased PD-L1 expression compared to empty-vector cells (Fig. 2, A and B) . PD-L1 expression decreased upon JAK2 inhibition (Fig. 2C) . In addition, PD-L1 expression and pSTAT3 in different human JAK2 V617F cell lines (UKE-1, SET-2, and MUTZ-8) could be reduced by specific JAK2 inhibition and ruxolitinib (Fig. 2, D to L). We tested the activity of the PD-L1 promoter using luciferase reporter assays ( fig. S5 ) in K562 cells. The activity of the PD-L1 promoter was higher in JAK2
V617F
-mutant K562 cells compared to empty-vector K562 cells (Fig. 2M) . PD-L1 promoter activity declined upon JAK2 and STAT3 inhibition (Fig. 2, N and O) .
In addition, we studied pSTAT1, pSTAT3, and pSTAT5 in K562 cells. We found that transfection of JAK2 V617F increased pSTAT3 and pSTAT5, but not pSTAT1 in K562 cells compared to empty vector ( fig. S6 , A to C). A STAT1 GOF mutation did not increase PD-L1 expression in K562 cells, whereas PD-L1 increased in the presence of STAT3 GOF and STAT5 GOF mutations ( fig. S6D ).
Multiple cell types express increased PD-L1 in MPN patients
Next, we analyzed PD-L1 expression on different primary human cells in the peripheral blood (PB) of MPN patients (patients' characteristics are shown in table S1). PD-L1 expression on PB cells and platelets was higher in JAK2 V617F MPN patients compared to healthy volunteers (Fig. 3, A and B) . We observed that T cells, monocytes, myeloid-derived suppressor cells (MDSCs), and platelets all had higher PD-L1 expression in MPN patients compared to healthy controls (Fig. 3C) . The slight increase of PD-L1 in human T cells and B cells in MPN patients compared to healthy controls (Fig. 3C ) is consistent with reports by others that B and T cells in some patients with MPN also carry the V617F mutation (22) . The high expression of PD-L1 on MDSCs and the previous report that MPN is also associated with increased numbers of MDSCs (23) point to immunosuppressive potential of these cells in MPN. In contrast to JAK2 V617F peripheral blood mononuclear cells (PBMCs), calreticulin (CALR)-mutated PBMCs did not exhibit increased PD-L1 expression compared to cells derived from healthy individuals ( fig. S7A) . Cells with genomic amplification of JAK2 had increased PD-L1 expression ( fig. S7B ) and caused MPN-related death in a xenograft model, which could be prevented by anti- PD-1 therapy (fig. S7C ).
Ruxolitinib treatment of MPN patients decreased PD-L1 expression on monocytes and platelets (Fig. 3, D and E) . Compatible with a causal connection between JAK2 activation, STAT3 phosphorylation, and PD-L1 expression, pSTAT3/STAT3 ratios decreased upon ruxolitinib treatment (Fig. 3, F and G) . Analysis of the BM from patients with different JAK2 V617F MPN entities and healthy BM donors showed that MPN patients had higher numbers of PD-L1 + cells and that the most common cell type expressing PD-L1 was the megakaryocyte (Fig. 3, H to J) .
Higher PD-L1 expression was associated with a more advanced MPN stage, as determined by histological signs and Dynamic International Prognostic Scoring System score ( fig. S8 , A to C) (24) . MPN patients had lower CD4 and CD8 T cell numbers 5 years after diagnosis compared to MPN patients analyzed within the first year after diagnosis, suggesting that immunotherapy may be more effective in the earlier stages ( fig. S8D) .
We next transferred JAK2 Cu-labeled anti-PD-L1 antibody showed the highest PD-L1 expression in the spleen (Fig. 4A) , which is an organ with a high disease burden in this MPN model. Mice with JAK2 V617F -transfected BM had higher PD-L1 expression (PET signal) in spleen and BM compared to WT-BM mice (Fig. 4B) . This result supports our previous in vitro findings and flow cytometry analysis with in vivo real-time data. Platelets had the highest PD-L1 expression in the JAK2 V617F -transfected BM MPN model (Fig. 4, C and D) . To verify these results in an additional model, we used an MPN model that relies on conditional expression of a JAK2 V617F knock-in mutation in hematopoietic cells, activated via the Cre/lox system by crossing JAK2-L2 with Mx-Cre mice (JAK2-FLEX/+ or L2/+) (25) . In this MPN model, we also observed that platelets had the highest expression of PD-L1 (Fig. 4, E and F) .
To understand why monocytes, platelets, and megakaryocytes have the highest PD-L1 expression, we studied the JAK2 V617F allele burden in different cell types of MPN patients. We found that platelets and monocytes had a higher JAK2 V617F allele burden than B cells, T cells, or neutrophils from the same patients (Fig. 4G) . We observed that human monocytes and platelets in the PB of MPN patients had higher pSTAT3 compared to B cells (CD19 (Fig. 4, H and I) .
MPNs are susceptible to PD-1 inhibition in the context of T cells
On the basis of the high PD-L1 expression of human MPN cells, we next tested our hypothesis that this disease is susceptible to therapeutic PD-1 inhibition. We transferred human PBMCs from three MPN patients who had relapsed after allo-HCT (patient characteristics are shown in fig. S10A) . We observed improved survival of mice treated with anti-PD-1 or anti-PD-L1 antibodies compared to mice treated with isotype IgG (Fig. 5, A to C) . Consistent with improved survival, we observed lower numbers of human platelets and CD45 + cells in the PB of mice treated with anti-PD-1 antibody compared to those of mice treated with isotype IgG (Fig. 5,  D and E) . In addition, we found reduced numbers of human CD45 + cells in BM of mice treated with anti-PD-1 antibody compared to those of mice treated with isotype IgG (Fig. 5, F and G) . Consistent with these findings, the JAK2 V617F allele burden was lower in mice treated with anti-PD-1 antibody than in mice treated with isotype IgG (Fig. 5H) . Immunohistochemistry-based analysis of the BM did not show a significant difference in human CD45 + cells in mice treated with anti-PD-1 antibody compared to the isotype IgG-treated group (Fig. 5, I and J).
The partial protection of mice treated with anti-PD-1 antibody compared to mice treated with isotype IgG was dependent on an intact donor T cell response, because depletion of CD3 + T cells from the transferred PBMCs ( fig. S10B ) removed the survival advantage of mice treated with anti-PD-1 antibody compared to mice treated with isotype IgG (Fig. 5K) . The graft-versus-host disease (GVHD) histopathology scores for RAG2 −/−
Il2rg
−/− mice that had received human MPN cells and human T cells were not different for mice treated with anti-PD-1 antibody or isotype IgG ( fig. S10C ).
To extend these results from the human xenograft model to another MPN model, we used the JAK2
V617F
-transfected syngeneic BM model. After full engraftment and development of MPN, defined by a hematocrit of more than 60% in the PB, the mice underwent antibody treatment. Survival of mice treated with anti-mouse PD-1 was improved compared to mice treated with isotype IgG (Fig. 5L) . We observed that the ratio of effector/naive CD8 + T cells increased in mice that were reconstituted with JAK2 V617F -transduced BM versus controls (Fig. 5M ). This indicates that more effector T cells developed in these mice, which may have generated an anti-MPN effect. This effect was connected to PD-L1 expression because the ratio of effector/naive CD8 + T cells increased further in mice treated with anti-mouse PD-L1 compared to mice treated with isotype IgG (Fig. 5M) . Shannon diversity index of complementarity determining region 3 amino acid sequences for T cell receptor (TCR)  chains was significantly (P = 0.04) lower in T cells of anti-PD-1-treated mice (Fig. 5,  N and O). These observations are in line with previous studies showing that T cell-mediated anti-leukemia response is linked to low TCR repertoire diversity (26) .
PD-L1-expressing JAK2
V617F -mutant cells affect cell cycle progression and metabolism in T cells
When T cells were exposed to JAK2 V617F myeloid 32D cells, unbiased gene expression analysis revealed a down-regulation of multiple gene sets that represent metabolic pathways (Fig. 6A) . One of the gene sets with reduced expression in T cells exposed to JAK2 V617F myeloid 32D cells was amino acid metabolism (Fig. 6A, asterisk) . In agreement
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with this finding, murine T cells exposed to JAK2 V617F Ba/F3 cells showed a down-regulation of genes related to methionine and cysteine metabolism, which are critical for T cell activation ( fig. S11A ) (27) (28) (29) . The alanine serine and cysteine transporter system SLC1A5 (ASCT2), which was down-regulated in T cells upon exposure to JAK2 V617F Ba/F3 cells, is essential for T cell activation (30). Expression of SLC1A5 on T cells declined in a cell dose-dependent manner when they were exposed to JAK2 V617F Ba/F3 cells ( fig. S11B ). Consistent with our findings, a functional link between amino acid metabolism and PD-1 activation has been reported (2) .
To understand whether mutant JAK2-induced PD-L1 expression had an impact on T cell metabolism, we determined the rates of oxidative phosphorylation in CD3 + T cells by measuring the oxygen consumption rate (OCR) at baseline and during a mitochondrial fitness test (31) . Basal OCR in mouse CD3 + T cells was decreased after exposure to JAK2 V617F 32D cells (Fig. 6B) or JAK2 V617F Ba/F3 cells ( fig.  S11, C and D) . Previous reports had shown that aerobic glycolysis is a hallmark of effector lymphocyte metabolism (31) , which was reduced in the T cells exposed to the JAK2 V617F 32D and JAK2 V617F Ba/F3 cells (Fig. 6B and fig. S11, C and D) . Because cell cycle progression is affected by PD-1 ligation on T cells, we next analyzed cell cycle-related genes. We observed that gene sets relevant for G 1 -to S-phase transition were down-regulated in mouse T cells (isolated from C3H mice) that were exposed to JAK2 V617F 32D (C3H background) cells (Fig. 6C ). Cyclin-dependent kinase 6 (CDK6), which is required for cell cycle progression in T cells, was down-regulated in T cells exposed to JAK2
V617F
Ba/F3 cells analyzed by gene expression array ( fig. S11E ). The gene expression of Cdk8 was also down-regulated in T cells when JAK2
Ba/F3 cells were present ( fig. S11E ). Conversely, gene expression of cyclin G2 (Ccng2), which induces cell cycle arrest, and cyclin-dependent kinase inhibitor 2D (Cdkn2d), which reduces cell cycle activity, was up-regulated in T cells exposed to JAK2 V617F Ba/F3 cells ( fig. S11F ). Consistently, we observed that the percentage of T cells in G 0 /G 1 phase increased when T cells were exposed to JAK2 V617F Ba/F3 cells ( fig. S11G ). This pattern was not observed when the T cells were PD-1-deficient ( fig. S11G) , indicating that the effect was mediated via PD-1.
To understand whether these findings could be reproduced in human cells, we cocultured human T cells from healthy donors with JAK2 V617F K562 cells. Respiration in human CD3 + T cells was decreased after exposure to JAK2 V617F K562 cells (Fig. 6D) . In addition, the percentage of T cells in G 0 /G 1 phase increased when T cells were exposed to JAK2 V617F K562 cells (Fig. 6E) . On the basis of our findings in the mouse model, we treated patient #1 (table S2) , who was initially diagnosed with polycythemia vera. He had undergone allo-HCT, relapsed, and was resistant to multiple salvage therapies (ruxolitinib, hydroxyurea, and decitabine). The anti-PD-1 antibody nivolumab was used as an individualized approach. At the start of treatment, 98% of the CD3 + cells were donorderived, whereas 50% of the CD34 + cells were recipient-derived ( fig.  S12A) . Immunohistochemistry of the BM showed the underlying MPN with a transformation into AML at the time of relapse. No additional mutations (besides JAK2 V617F ) in the PBMCs were found by using a 48-gene myeloid panel sequencing approach that was confirmed by whole-exome sequencing. In agreement with the findings in mice, in a patient with polycythemia vera we observed that recipient chimerism, JAK2 V617F allele burden, CD34
+ cells in the PB, and cellularity in the BM all decreased after nivolumab treatment ( fig.  S12, A to G) . Conversely, the number of total CD3 + cells in the PB increased after application of nivolumab ( fig. S12, H and I) .
On the basis of our findings, we propose a scenario where oncogenic JAK2 activity results in STAT3 and STAT5 phosphorylation, which in turn enhances PD-L1 promoter activity (Fig. 6G) . The cells carrying JAK2
V617F express PD-L1 and thereby inhibit amino acid and glucose metabolism and cell cycle progression-promoting genes in T cells.
DISCUSSION
Once a cell has acquired an oncogenic mutation allowing for uncontrolled proliferation and avoidance of apoptosis, a critical next step in the development toward neoplastic disease is to escape the immune system. Because both events, oncogenic transformation and immune escape, have to occur at the beginning of neoplastic development, it is likely that certain oncogenic mutations cooperate with mechanisms that allow immune escape. We found that oncogenic JAK2 activation results in high expression of PD-L1, mainly on the surface of monocytes, MDSCs, megakaryocytes, and platelets, and that this is mediated via the JAK2-STAT3 and JAK2-STAT5 axes. Consistent with our findings, others showed that pSTAT3 binds to and activates the PD-L1 gene promoter (32, 33) . Because JAK2 is a canonical STAT3 activator and STAT3 activates PD-L1 transcription, the induction of PD-L1 in MPN was likely, and our study shows this connection experimentally in a systematic analysis of JAK2 V617F -mutant cells. Recently, a binding site for STAT5 was found in the PD-L1 promoter region (18) , but no functional connection between STAT5 activation and PD-L1 expression had been reported to date. We observed a minor role for STAT5 in PD-L1 expression, which was less prominent compared to the role of STAT3.
A limitation of the study is that we cannot clarify why AMLs do not exhibit high expression of PD-L1. A possible explanation is that other regulatory mechanisms for PD-L1 are active in AMLs. Interference with CMTM6 expression results in impaired PD-L1 protein expression because CMTM6 prevents PD-L1 from being targeted for lysosome-mediated degradation (34, 35) . Therefore, cells with a low amount of CMTM6 will have more PD-L1 degradation even if STAT3 activation is present. Another limitation of our study is that we used xenograft models of MPN, which are artificial because the recipient mice are immunodeficient. To correct for this, we had transferred T cells along with the MPN cells to allow for immune-mediated effects. An additional limitation is that our findings can only be applied to JAK2 V617F -mutant MPN, and we did not clarify which immune escape mechanisms are active in JAK2-negative MPN.
For a variety of tumor entities such as non-small cell lung cancer (36) and Hodgkin's lymphoma (9) , high expression of PD-L1 favors sensitivity of the malignancy to PD-1 inhibition. In particular, increased expression of PD-L1 on hematopoietic cells was associated with increased response (37) . This is consistent with our finding showing that PD-L1 expression on cells was high in MPN, which then responded to PD-1 inhibition in an allo-HCT patient who had relapsed after transplant. Previous work had shown that T cell-mediated immunosurveillance plays a central role in MPN progression, because T cells recognizing mutant JAK2 can be found in MPN patients (12) , and MPNs are immunogenic because they respond to IFN-2b (11) .
Our observation that PD-L1 expression is high on megakaryocytes is consistent with previous reports indicating that this cell type is an important disease-driving force in MPN (38, 39) . However, other cell types, such as monocytes, MDSCs, and lymphocytes, expressed PD-L1, which is consistent with the fact that these cells also have a certain JAK2 V617F allele burden (22) . When murine or human T cells were exposed to PD-L1 high cells with mutant JAK2, we observed major changes in metabolism, senescence, IFN- production, and cell cycle activity. In particular, cysteine metabolism was reduced when murine T cells were exposed to PD-L1 high JAK2 V617F cells. This may be a major mechanism for JAK2 V617F cells to affect T cell activation because cysteine is the limiting precursor for glutathione synthesis, a prerequisite for antigen-dependent proliferation of T cells (29) . The decreased OCR we observed in T cells exposed to JAK2 V617F cells indicates that these T cells were overall less metabolically active, which is consistent with the idea that there is decreased cell cycle activity in this T cell population. Reduced proliferative capacity due to cell cycle inhibition may contribute to the reduced antitumor activity of T cells exposed to PD-L1 high JAK2 V617F cells. DNA methyltransferase inhibitor treatment can also up-regulate PD-L1 expression in MDS, possibly causing disease resistance (40) . Checkpoint inhibition can induce response rates above 50%, as recently reported for patients with different hematologic malignancies treated with an anti-CTLA-4 antibody after allo-HCT (41) . We showed that activation of the JAK2/STAT3 and JAK2/STAT5 axes causes PD-L1-mediated immune escape in MPN. We defined megakaryocytes, platelets, and monocytes as the cell populations with the highest PD-L1 expression and characterized a gene signature in T cells that were affected by the PD-L1-expressing cells. Furthermore, we reported the susceptibility of MPN to PD-1 inhibition, which should serve as a basis for immunotherapeutic approaches that rely on PD-1 inhibition in this disease entity.
MATERIALS AND METHODS
Study design
For the sample size in the murine survival experiments, a power analysis was performed. A sample size of at least n = 8 per group was determined to reach a statistical significance of 0.05 to detect an effect size of at least 1.06 with 80% power. Mice were assigned randomly to the experimental groups. All samples and mice were included in our analysis. Experiments were performed in a nonblinded fashion, except for the blinded GVHD severity scoring.
Human subjects
Human sample collection and analysis were approved by the ethics committee of the University of Freiburg, Germany (protocol numbers 10024/13 and 558/15). Blood was collected from MPN patients or healthy volunteers after informed consent.
Statistical analysis
GraphPad Prism v5.03 was used for statistical analysis. Normally distributed data were analyzed using the unpaired two-tailed t test. When the data did not conform to a normal distribution, the Mann-Whitney U test was used. Differences in mouse survival (Kaplan-Meier survival curves) were analyzed by log-rank test. Data are presented as means and SEM, unless otherwise indicated. P < 0.05 was considered to be statistically significant.
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